NL-OMON36244已完成3 期
An Extension Protocol for Participants of Genzyme-Sponsored;Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® implant) for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea - MACI00809
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Genzyme
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients must meet the following criteria to participate in this extension study:;1. Received study treatment (MACI implant or microfracture) in the MACI00206 study.;2. Provides written informed consent.
排除标准
- •Exclusion Criteria, not applicable for this extension study.
研究者
相似试验
进行中（未招募）
不适用
SUMMIT Extension StudySymptomatic Articular Cartilage Defects of the Femoral Condyle including the Trochlea.Osteochondritis dissecans lesions that do not require a bone graft.MedDRA version: 18.0Level: LLTClassification code 10031231Term: Osteochondritis dissecansSystem Organ Class: 100000004859MedDRA version: 18.0Level: LLTClassification code 10007705Term: Cartilage damageSystem Organ Class: 100000004863EUCTR2009-016970-33-SEVericel Corporation144
进行中（未招募）
不适用
SUMMIT Extension StudyEUCTR2009-016970-33-NLGenzyme Europe BV142
进行中（未招募）
不适用
SUMMIT Extension StudySymptomatic Articular Cartilage Defects of the Femoral Condyle including the Trochlea.Osteochondritis dissecans lesions that do not require a bone graft.MedDRA version: 18.0Level: LLTClassification code 10031231Term: Osteochondritis dissecansSystem Organ Class: 100000004859MedDRA version: 18.0Level: LLTClassification code 10007705Term: Cartilage damageSystem Organ Class: 100000004863EUCTR2009-016970-33-CZVericel Corporation144
进行中（未招募）
不适用
SUMMIT Extension StudyEUCTR2009-016970-33-PLGenzyme Europe142
进行中（未招募）
1 期
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols - N/AEUCTR2010-020151-31-DEArQule, Inc.60